Xcout Intel
immunitoAI competitors & alternatives
The 12 closest competitors and alternatives to immunitoAI among biotechnology companies — ranked by similarity to what immunitoAI actually does, not by market-cap band.
Subscribe to see immunitoAI’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About immunitoAI
immunitoAI is a TechBio research company founded in 2020 that develops AI-driven platforms to unlock the potential of antibody therapeutics. Headquartered in Bengaluru, Karnataka, India, the company employs a team of 11 to 50 professionals.
immunitoAI at a glance
immunitoAI is a biotechnology company headquartered in India. It has raised at least $7.1M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $6.1M in November 2025. Xcout tracks 4 named people at immunitoAI, including Dr. Abhishek Mathur (CSO).
immunitoAI leadership
- Dr. Abhishek MathurCSO
- Dr. Aridni ShahCo-Founder and CEO
- Trisha ChatterjeeCo-Founder and CTO
- Aridni ShahCo-Founder
immunitoAI funding rounds
At least $7.1M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $6.1M | 4 named | |
| — | $1M | 9 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 immunitoAI competitors
Ranked by semantic similarity — how close each company is to immunitoAI by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Prellis Biologics, Inc. is a privately held biotechnology company headquartered in Berkeley, California, within the San Francisco Bay Area. It develops human antibody therapeutics and focuses on antibody discovery leveraging AI and immune diversity.
Similar biotechnology company
Biolojic Design is an Israeli biotechnology company that uses computational modeling and artificial intelligence to design and engineer antibodies and other therapeutic proteins. It develops drug candidates and collaborates with pharmaceutical and biotechnology companies seeking novel biologic medicines.
Similar biotechnology company
Monocacy Therapeutics Inc. develops artificial intelligence-guided, first-in-class immune medicines designed to restore optimal immune function and patient health. The company utilizes a full-stack, AI-powered immunology platform to discover and develop next-generation immunotherapies for patients.
Biotech
Antiverse is a biotechnology research company headquartered in Cardiff, Wales, that utilizes generative artificial intelligence to design functional antibodies for challenging drug targets.
Similar biotechnology company
CombinAble.AI is an Israeli biotechnology startup incubated within AION Labs that develops a novel approach to biological drug discovery through the design and optimization of antibodies. The company leverages artificial intelligence to accelerate the development process for biological therapeutics and was acquired by Insitro.
Similar biotechnology company
BigHat Biosciences, Inc. is a for-profit biotechnology company located in California. The firm leverages machine learning and synthetic biology to design next-generation antibody therapies.
Biotech
Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission is to facilitate the delivery and application of active agents within carbon-based life forms, operating in both the Chinese Mainland and the United States. Central to its offerings is NanoForge, a comprehensive suite of interconnected technologies that includes a novel lipid library, foundational artificial intelligence models, METiSAIAgent, cutting-edge quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. Furthermore, Metis TechBio has developed specialized platforms like AiTEM, AiLNP, and AiRNA. These tools are crucial for simulating, predicting, and interpreting interactions at the nanoscale, thereby enabling the precise design, optimization, and validation of sophisticated nanomaterials and their associated payloads. The company provides its services through a three-tiered system: a foundational dry-wet data layer supported by integrated laboratory infrastructure, a model layer featuring METiS AI foundational models, and an application layer known as METiSAgentv. Metis TechBio primarily serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and medical research institutions.
Similar biotechnology company
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Similar biotechnology company
Matchpoint Therapeutics Inc. discovers and develops precision small molecule medicines utilizing covalent chemistry and chemoproteomics screening to treat immune diseases. The company leverages proprietary screening technologies and machine learning algorithms to expand the druggable proteome and design covalent drug candidates for patients with serious inflammatory and immune conditions.
Similar biotechnology company
Revalia Bio is a biotechnology research company using artificial intelligence to transform donated human biology data. It has a company size of 11-50 employees and is headquartered in New Haven, Connecticut.
Biotech
Atomic AI is a biotechnology research company specializing in RNA drug discovery utilizing atomic precision. Headquartered in San Francisco, California, the company combines machine learning and biology to develop advanced therapeutics.
Similar biotechnology company
9Bio Therapeutics is a biotechnology company that combines biology, structural engineering, and artificial intelligence to pioneer next-generation biologics for advanced cancers. The company is headquartered in Quebec, Canada.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of immunitoAI and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for immunitoAIand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →